Supplementary Figure S3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure S3. Subgroup analyses of overall survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology group; PS, performance status; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CNS, central nervous system.